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Ki67a b s t r a c t
Background: The WHO has recognized a variant of pituitary adenomas with potential aggressive beha-
viour which have been termed atypical pituitary adenomas. This group of tumours are recognized by
their mitotic rate of more than >3%, p53 expression and invasion of surrounding structures. There has
however been no study of the occurrence of these tumours in a black African population. This study is
a preliminary attempt to examine this group of tumours in blacks.
Methods: This study retrospectively reviewed fifty-seven histologically diagnosed and immunohisto-
chemically characterized pituitary adenomas received in our department over a twenty-one year period.
Specimens were stained with ki67, a nuclear marker of cell proliferation which has been identified as the
single best predictor of atypical pituitary adenoma.
Results: Twelve of the tumours showed atypical features with eight (67%) of these tumours being pro-
lactinomas. Two of the tumours were gonadotrophs and two were null cell adenomas. There was no cor-
relation with age or gender. Two of the tumours required neurosurgical re-exploration with one of these
showing a higher mitotic index in the second biopsy.
Conclusion: The study suggests similarity in the rate of occurrence of pituitary adenomas with atypical
features in a black African population with what is seen in Caucasians. Prolactinomas constitute a signif-
icant percentage of the tumours with this feature.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The most common tumour occurring in the sellar area is the
pituitary adenoma and it constitutes about 10–15% of all intracra-
nial tumours.1–3 Pituitary adenomas are benign epithelial tumours
composed of adenohypophyseal cells, some of which secrete hor-
monal substances.3,4 Most of the tumours are slow growing with
the cells appearing monomorphic. They often grow in an expansive
pattern and do not invade surrounding structures. Occasional
tumours show invasion of surrounding structures with increase
in proliferation.4 The WHO classification of 2004 has identified this
group of tumours as atypical adenomas and they are characterized
by local invasion and increased mitosis.5,6 The atypical adenomas
usually show an increased MIB-1 labelling index of more than 3%and often show p53 reactivity which is not seen in benign
tumours.2,5 This group of tumours are known to confer a poor
prognosis due to their high recurrence rate.7 There is no proof at
present to describe these tumours as premalignant lesions despite
their clinical behaviour. However, the clinical relevance of these
tumours has been questioned based on studies which have not
been able to show any correlation with invasiveness and rate of
proliferation.7–9 Several studies have shown that the ki67 index
is the single best predictor of atypia in pituitary adenoma com-
pared with the other parameters.10,11
Many studies have shown prolactinomas, and corticotroph ade-
nomas as the most common tumours showing atypical features,
while null cell and gonadotroph adenomas as the least common;
others have shown lack of uniformity in the secretory status of
cells showing invasion.2,12,5,13 No study has been carried out in
an African population to determine the occurrence of this variant
of pituitary adenomas in the black African population. This is a pre-
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with atypical features in a predominantly black African population.Table 12. Materials and method
This study was conducted on immunohistochemically charac-
terized pituitary adenomas from surgical specimens obtained at
the University College Hospital, Ibadan over a twenty-one year
period. The tumours were removed via Pterional craniotomy with
microsurgical total tumour removal for the giant tumours and
endoscopic trans-septal trans-sphenoidal pituitary resection for
the intrasellar tumours. The pituitary adenomas had been identi-
fied according to the earlier described method.14 Ethical approval
for the study was obtained from the joint University of Ibadan/
University College Hospital ethical committee. The age, sex and
clinical history of the patients were obtained from their records.
There was no record of accompanying dura in the gross description
of any of the biopsies. The archived slides and paraffin wax blocks
were retrieved and the slides were reviewed to ascertain the accu-
racy of the initial diagnoses.
Each of the tissue blocks was stained with antibodies for ki67.
The streptavidin-biotin-peroxidase method was used and the pro-
tocol followed that of previous researchers.12,13,15
Three serial sections, cut at 5 lm each, were obtained from the
archived paraffin blocks for each case and deparaffinised. Antigen
unmasking, using the heat induced epitope retrieval method, was
done by first pre heating the retrieval buffer to a temp of 90–
95 C in an incubator (microwave) and subsequently immersing
the slides in preheated citrate buffer diluted to 1:10 with distilled
water for 10–20 min. They were then allowed to cool for 20 min in
cold water and thereafter rinsed in TBST (Tris buffered saline with
Tween). Blocking of enzyme activities/peroxidase was done with
3% hydrogen peroxide for 10–15 min. Each specimen was incu-
bated for 20–30 min with 40–130 ll of an appropriately character-
ized and diluted (1:200) KI67 rabbit primary antibody
(Thermofisher scientific Clone SP6). This was followed by incuba-
tion with an undiluted labelled polymer Horse Radish Peroxidase
(HRP) conjugated anti-mouse secondary antibody for 30 min.
Diaminobenzidene [DAB] solution was added to cover the speci-
men. Counterstaining was done with Haematoxylin. A tonsil
biopsy with a histological diagnosis of reactive follicular hyper-
plasia and a normal pituitary gland were used as positive and neg-
ative controls respectively.
The proliferation index was assessed using a modification of the
earlier described methods.8,9 A total of 1000 nuclei from the neo-
plastic cells were counted from ten randomly selected fields with
the aid of a graticle. This was done on each slide at 40 magnifica-
tion. The total number of stained nuclei was expressed as a per-
centage of the absolute number of counted nuclei. Using
modified 2004 World Health Organisation criteria, adenomas with
a Ki67 index of P3% were classified as atypical adenomas.6 Statis-
tical analysis was performed using Student t-test for comparison of
continuous variables and chi-squared test for comparison of dis-
continuous variables, to determine whether there was any associ-
ation between the clinical and immunohistochemical data. The
level of statistical significance was set at p 6 0.05.Distribution of benign and atypical adenoma according to age in decades.








71–80 0 13. Result
A total of 134 patients were diagnosed with pituitary adenoma
from the institutional cancer registry record during the study per-
iod. However only seventy-two of the biopsies were received in the
surgical department during the study period (many of the patients
received drug therapy while some defaulted and were lost to fol-
low up). Fifty-seven of the surgical biopsies of pituitary adenomaswere included in the study. Fifteen of the biopsies were excluded
either due to unavailability of their tissue blocks while some had
been exhausted during earlier diagnostic procedures. The speci-
mens were obtained from patients with ages ranging from 9 to
73 yrs. The tumours occurred more frequently in patients in their
fifth decade with 17 (30%) pituitary adenomas seen in this age
group (Table 1).
The ki67 index in the tumours ranged from 0.2 to 10.2 with a
mean index of 2.05. The benign tumours were 45 (79%) while the
pituitary adenomas with atypia constituted 12 (21%). Eight of the
pituitary adenomas with atypia (67%) occurred in patients in the
fourth and fifth decades. There was however no statistical signifi-
cance between the age and the level of atypia in these tumours
(p = 0.456). Thirty (52.6%) of the tumours were from female
patients while 27 (47.4%) were obtained from male patients. Seven
of the pituitary adenomas with atypical features occurred in
females while five occurred in males (Fig. 1). There was no statis-
tical significance between the sex and tumour atypia (p = 0.751).
Eight (67%) of the pituitary adenomas with atypia showed pos-
itive staining for prolactin. This was significant (p = 0.001). Only
two gonadotroph and null cell adenomas had atypical features,
even though they are the most frequent adenomas seen (Table 2).
Twenty-two (38.6%) of the pituitary adenomas showed micro-
scopic dural invasion while only three (13.6%) of these invasive
tumours showed high ki67 index.
Four out of the fifty-seven pituitary adenomas had surgical re-
exploration with two of these tumours having features of atypia.
Only one of the recurrent adenoma with atypical features was a
prolactinoma while the other was a null cell adenoma. The lone
case of prolactinoma required re-exploration after the pathologist
identified the tumour as atypical and the second biopsy from the
re-exploration showed a markedly higher index score (Fig. 2).4. Discussion
Invasive pituitary adenomas do not show typical histological
features of malignancy that identify tumours in other organs.18
The exact pathway that determines progression in pituitary adeno-
mas is yet to be fully understood although the Ras gene mutation
has been identified in some cases of pituitary carcinoma.4,19 Ikeda
and Yoshimoto have also demonstrated that adenomas with
increased ki67 index tend to show increased expression of both
c-myc and bcl-2 genes.20 Protein kinase C (PKC) and Pituitary
Tumour Transforming Gene (PTTG-1) are among the few other
identified gene mutations associated with increased aggressive-
ness.1,4,21 Several growth factors have however been associated
with increased ki67 index including epithelial growth factor recep-
tor (EGFR) and isoforms of basic fibroblast growth factor receptor
(FGFR4).4,19,21
The 2004 WHO definition of atypical adenomas identified sev-
eral characteristics which include high mitotic rate, ki67 index
greater than 3%, increased expression of p53 gene or gross invasion
of neighbouring structures.6,21 The proliferation index can be mea-
Figure 1. Sex distribution of the patients with pituitary adenoma variants in the
study.
Table 2
Hormone expression of pituitary adenomas in the study.






Figure 2. Ki67 expression in an atypical adenoma with nuclear staining of
proliferating cells in the cell cycle. 400 magnification.
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many studies have shown the greater utility of ki67, a nuclear mar-
ker that is active at all the stages of cell division.15,22–24 Our study
used ki67 proliferation rate alone which has been shown in some
studies as the best single predictor of atypical behaviour in pitu-
itary adenoma.10,11
Eight of the twelve adenomas with atypical features identified
in this study were prolactinomas which is in keeping with earlier
studies which noted that prolactinomas and ACTH adenomas tend
to have higher MIB index compared to the other tumour types
while null cell and gonadotroph adenomas often show low val-
ues.1,4,7 Other studies, however do not agree with this finding
and have shown that the rate of atypical features seen in different
adenoma groups vary, although some tumour types such as the
silent corticotroph adenomas are more likely to show atypia.17,22
Although none of the specimen seen in our study had evidence
of gross dural invasion, some of the tumours showed microscopic
dural invasion. The percentage of the tumours seen in this studywith this feature (38.6%) is much lower than the 85% observed in
the study by Scheithauer et al. for dural invasion of all pituitary
adenoma tumour types.18 Their study also noted that the incidence
of dural invasion is often under reported due to the fragmented
nature of the specimen usually received, which emphasizes the
importance of very careful observation by the pathologists for
detection of microscopic dural invasion.18 Another possibility
may be the absence of dura in the biopsy specimen received by
the pathologist. This may have also contributed to the low number
of tumours with microscopic dural invasion identified in this
study. It is noteworthy however, that the 2004 WHO classification
does not consider microscopic dural invasion a criterion for desig-
nation of atypia.6 Neuroradiological and surgical observation, with
the operating microscope, of gross dural invasion is however con-
sidered a feature of invasiveness.6,16
Several workers have shown a lack of correlation between MIB
labelling index in pituitary adenomas and the incidence of tumour
recurrence, after surgical removal.8,9,12,13 The lack of consistency in
the behaviour of the tumours has made many clinicians to re-
consider the usefulness of the MIB index in pituitary adenomas
to patient management.7 In our series the prolactinoma with atyp-
ical features which required re-exploration was detected via its
high proliferation index. The increase in the proliferation rate of
the second biopsy showed a potentially aggressive tumour; a point
in favour of the prognostic value of the MIB index.
4.1. Limitations
The number of samples in this study is small and epidemiolog-
ical conclusions could not be made based on our results. The study
however serves as a preliminary study on the occurrence of pitu-
itary adenomas with atypical features in blacks. The study was
conducted in a national center catering to patients from distant
parts of the country who are often lost to follow up after discharge
due to distance. A true description of the rate of recurrence of this
group of tumours cannot be proffered in this study.
4.2. Conclusion
The behaviour of pituitary adenomas is yet to be fully under-
stood. However, it appears that the occurrence of pituitary ade-
noma with atypical features in a predominantly black population,
as shown in this study, is similar to what is seen in Caucasian pop-
ulations. However, due to the low number of samples in this study,
an epidemiological conclusion cannot be made. There is a need for
a larger study with a view to deriving more definitive epidemiolog-
ical data and characterizing the genetics of pituitary adenomas in
this patient population represented by our study subjects.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ajme.2016.11.
003.
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